Pemba – Accelagen
WA-45043
Curis BidCo Pty Ltd (**BidCo**) proposes to acquire 100% of the issued shares in Accelagen Pty Ltd (**Accelagen**) from Accelagen’s existing founding shareholders (the **Acquisition**). BidCo is a special purpose vehicle and is an indirect wholly owned subsidiary of Curis HoldCo Pty Ltd (**HoldCo**). HoldCo is currently wholly owned by Pemba Capital Fund IV, L.P., a private equity fund managed by Pemba Capital Partners Pty Ltd (**Pemba**), based in Sydney. The Acquisition will be implemented by way of a Share Purchase Deed. Following completion, BidCo will exercise control of Accelagen. Pemba is an investor in high-growth and entrepreneurial businesses, with over AUD 2 billion in assets under management. Pemba has interests across various sectors, including business services, education & training, financial services, healthcare, and technology. Accelagen is an Australian-based, full-service contract research organisation (**CRO**), with a focus on clinical development and regulatory affairs, providing guidance and support throughout all stages of product development to biotechnology, pharmaceutical and medical device companies, including the development, initiation and management of Phase I-IV clinical trials.
Status
Assessment completed
Determination
Approved
Stage
Waiver application
Notified
30 October 2026
Acquirers
- Curis BidCo Pty Ltd
Targets
- Accelagen Pty Ltd